Efficacy and Safety of Topical Nicotinamide in Treatment of Discoid Lupus Erythematosus

• Status: Recruiting
• Trial end date: 2022-09-30
• Target enrollment: 0
• Participant gender: All

Summary

Cutaneous lupus erythematosus (CLE) is lupus affecting the skin. In this autoimmune disease, the body's immune system attacks healthy skin. There are 3 main types: Acute cutaneous lupus, Subacute cutaneous lupus, and Chronic cutaneous lupus ("discoid lupus"). Lupus most often appears between the ages of 20 and 50 years; it affects women more than men, and it may happen more in patients with a family history of lupus or other autoimmune diseases.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Al-Azhar University
• Treatments: Niacin; Niacinamide; Nicotinic Acids

Criteria

Inclusion Criteria:

• Age: between 18 years and 65 years old

• Patients clinically and histopathologically newly diagnosed as DLE

• Patients clinically and histopathologically diagnosed with cutaneous lupus erythematosus that has not responded to treatment with hydroxychloroquine(200-400mg/day) plus corticosteroid at a dosage less than the equivalent of (0.5mg/kg/day) for the preceding two months or a longer period

Exclusion Criteria:

• Age < 18 years old

• Pregnant and lactating women

• A history of treatments with multivitamins in the recent month

• Soft tissue infection

• Severe comorbidities including heart failure, respiratory failure

• Acute severe infections such as cellulitis or a history of HBV or HCV